OrthoPediatrics (KIDS) Projected to Post Quarterly Earnings on Wednesday

OrthoPediatrics (NASDAQ:KIDS) is projected to announce its Q1 2025 earnings results after the market closes on Wednesday, May 7th. Analysts expect the company to announce earnings of ($0.38) per share and revenue of $51.68 million for the quarter. OrthoPediatrics has set its FY 2025 guidance at EPS.

OrthoPediatrics (NASDAQ:KIDS) last posted its quarterly earnings results on Tuesday, March 4th. The company reported ($0.29) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.33) by $0.04. The business had revenue of $52.67 million for the quarter, compared to analysts’ expectations of $51.16 million. OrthoPediatrics had a negative return on equity of 5.78% and a negative net margin of 15.00%. During the same quarter last year, the business earned ($0.23) earnings per share. On average, analysts expect OrthoPediatrics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

OrthoPediatrics Price Performance

OrthoPediatrics stock opened at $21.55 on Wednesday. The business’s 50-day simple moving average is $23.38 and its 200 day simple moving average is $24.38. The stock has a market cap of $523.38 million, a price-to-earnings ratio of -17.52 and a beta of 1.17. OrthoPediatrics has a 12-month low of $20.25 and a 12-month high of $35.99. The company has a quick ratio of 3.68, a current ratio of 7.17 and a debt-to-equity ratio of 0.19.

Insiders Place Their Bets

In other OrthoPediatrics news, CEO David R. Bailey sold 6,620 shares of the firm’s stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $24.86, for a total transaction of $164,573.20. Following the transaction, the chief executive officer now owns 319,155 shares in the company, valued at approximately $7,934,193.30. This trade represents a 2.03 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Fred Hite sold 6,443 shares of OrthoPediatrics stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $24.86, for a total value of $160,172.98. Following the transaction, the chief financial officer now owns 207,989 shares in the company, valued at $5,170,606.54. This trade represents a 3.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,732 shares of company stock worth $589,978. Insiders own 31.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Stifel Nicolaus decreased their price target on OrthoPediatrics from $40.00 to $32.00 and set a “buy” rating on the stock in a report on Wednesday, March 5th. Truist Financial decreased their price target on OrthoPediatrics from $26.00 to $24.00 and set a “hold” rating on the stock in a report on Friday, April 11th. Needham & Company LLC restated a “buy” rating and set a $42.00 target price on shares of OrthoPediatrics in a report on Wednesday, April 9th. Finally, Lake Street Capital assumed coverage on OrthoPediatrics in a report on Monday, April 7th. They set a “buy” rating and a $37.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $37.00.

About OrthoPediatrics

OrthoPediatrics Corp., a medical device company, engages in designing, developing, and marketing anatomically appropriate implants, instruments, and specialized braces for children with orthopedic conditions in the United States and internationally. The company offers pediatric trauma and deformity correction products; scoliosis procedures for the treatment of spinal deformity; and sports medicine and other products.